Status:
COMPLETED
Effects of Fibromyalgia Syndrome in Patients With Systemic Sclerosis
Lead Sponsor:
Antalya Training and Research Hospital
Conditions:
Systemic Sclerosis
Fibromyalgia
Eligibility:
FEMALE
18-65 years
Brief Summary
Systemic sclerosis \[SSc\]; is a multisystem disease characterized by immune activation, microvascular disease and fibroblast dysfunction, which is thought to occur as a result of complex and not full...
Detailed Description
There are a few studies on this subject. Except for one of these studies, the sensitive point in ACR 1990 FMS diagnostic criteria set was evaluated. In 2010, ACR published new criteria, which may be a...
Eligibility Criteria
Inclusion
- SSc diagnosis is definitive and diffuse involvement
- no additional disease known other than scleroderma (Diabetes mellitus, hypertension etc.)
- no known additional rheumatic diseases
Exclusion
- To have depression and / or any psychiatric illness
- To use steroid, antidepressant, antiepileptic, regular NSAID usage.
Key Trial Info
Start Date :
January 2 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 20 2019
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT04411498
Start Date
January 2 2019
End Date
December 20 2019
Last Update
November 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ethics Commitee of Antalya Training and Research Hospital
Antalya, Turkey (Türkiye)